相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial
Gilberto de Castro Junior et al.
EUROPEAN JOURNAL OF CANCER (2018)
EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo
Chenfei Zhou et al.
CURRENT CANCER DRUG TARGETS (2017)
Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial
Mohan Suntharalingam et al.
JAMA ONCOLOGY (2017)
Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World
Yaimarelis Saumell et al.
ADVANCES IN THERAPY (2017)
Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy plus /- cetuximab in oesophageal cancer
T. Crosby et al.
BRITISH JOURNAL OF CANCER (2017)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial
Ming Lu et al.
CANCER SCIENCE (2016)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
Surgical Treatment of Moderate Ischemic Mitral Regurgitation
P. K. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
EGF receptor trafficking: consequences for signaling and cancer
Alejandra Tomas et al.
TRENDS IN CELL BIOLOGY (2014)
Phase II Trial of Cetuximab in Patients With Metastatic or Locally Advanced Soft Tissue or Bone Sarcoma
Huan T. Ha et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
Thomas Crosby et al.
LANCET ONCOLOGY (2013)
Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail
Xue Meng et al.
RADIOTHERAPY AND ONCOLOGY (2013)
Treatment of malignant, non-resectable, epithelial origin esophageal tumors with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy
Mayra Ramos-Suzarte et al.
CANCER BIOLOGY & THERAPY (2012)
17α-Alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism
Clarence Ahlem et al.
INVESTIGATIONAL NEW DRUGS (2012)
Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3
Lei Zhao et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Bivalent binding by intermediate affinity of nimotuzumab A contribution to explain antibody clinical profile
Greta Garrido et al.
CANCER BIOLOGY & THERAPY (2011)
Nimotuzumab and Cetuximab Block Ligand-independent EGF Receptor Signaling Efficiently at Different Concentrations
Christian Berger et al.
JOURNAL OF IMMUNOTHERAPY (2011)
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects
Rolando Perez et al.
Cancers (2011)
Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery
Arend H. Sikkema et al.
CANCER RESEARCH (2009)
Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity
Howard Safran et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation
Takaomi Okawa et al.
GENES & DEVELOPMENT (2007)
EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus
M Hanawa et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma
P Sunpaweravong et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
分享论文
